Clinical Context
Pediatric type 1 diabetes management remains challenging despite advances in technology. While continuous glucose monitoring (CGM) provides unprecedented visibility into glucose patterns, the data alone doesn’t improve outcomes—it’s what patients and families do with the data that matters. Many children and adolescents with type 1 diabetes remain above target, with mean HbA1c levels in pediatric diabetes registries typically ranging from 8.0-9.0%, well above the recommended target of less than 7.0%.
The traditional model of quarterly clinic visits leaves families to navigate daily diabetes management largely on their own between appointments. This interval is too long to address the rapidly evolving challenges of childhood—growth spurts, changing activity levels, school schedules, and the unique social pressures of adolescence all affect insulin requirements. By the time a quarterly visit arrives, patterns identified in CGM data may already be outdated.
Telehealth offers the potential to bridge this gap, providing more frequent touchpoints without the burden of clinic visits. The COVID-19 pandemic accelerated telehealth adoption, but questions remain about optimal frequency, structure, and which patients benefit most. This randomized crossover trial directly tests whether weekly telehealth support can improve glycemic outcomes in children with suboptimal control using CGM and multiple daily injections.
Study Summary (PICO Framework)
Summary:
In children and adolescents with poorly controlled type 1 diabetes (mean HbA1c 9.4%) using CGM and MDI, 12 weeks of weekly 20-minute telehealth consultations with structured CGM review significantly reduced HbA1c by 0.29%, increased time in range, and decreased glucose variability compared to routine care alone, with no increase in hypoglycemia.
| PICO | Description |
|---|---|
| Population | Children and adolescents (mean age 11.8 years) with T1D duration ~3.5 years, using FreeStyle Libre 2 CGM and MDI, with suboptimal control (mean HbA1c 9.4%). |
| Intervention | Weekly telehealth: 20-minute phone consultations with diabetes educator, structured CGM data review, and digital education for 12 weeks. |
| Comparison | Routine care without additional telehealth intervention (crossover design—participants served as own controls). |
| Outcome | HbA1c reduction -0.29% (p<0.001). Improved TIR, decreased TAR, reduced glucose variability and GMI. Time below range unchanged (no increased hypoglycemia). |
Clinical Pearls
1. Weekly contact intensity drives improvement. The key differentiator in this study was frequency of contact—weekly rather than quarterly. Each 20-minute session reviewed the past week’s CGM data and made real-time adjustments. This rapid feedback loop allows dose titration before problematic patterns become entrenched and provides accountability that helps families maintain engagement. The message: data review must be frequent and actionable to matter.
2. Improvement without increasing hypoglycemia is the holy grail. One of the most important findings was that time below range (TBR) remained unchanged despite significant reductions in hyperglycemia. This indicates that the intervention improved control through better management—more precise dosing, better timing, improved carb counting—rather than simply increasing insulin doses that would risk hypoglycemia. Achieving “more time in range” rather than “lower average glucose” is the right goal.
3. Structured approach matters more than casual check-ins. The intervention wasn’t just “call to see how things are going.” It was a structured review of CGM metrics, ambulatory glucose profile patterns, and specific dose adjustments. Diabetes educators followed a protocol that ensured consistent, actionable feedback. Unstructured telehealth visits may be less effective; the structured approach is reproducible and trainable.
4. High-risk patients derive the most benefit. The study population had a mean HbA1c of 9.4%—significantly above target. These are the patients who have the most room for improvement and for whom the barriers to good control (knowledge gaps, dose inertia, disengagement) are most amenable to intensive support. Well-controlled patients may not need or benefit from weekly contact.
Practical Application
Identifying candidates: Consider intensive telehealth support for pediatric patients with HbA1c consistently above 8.5%, declining glycemic trends, newly diagnosed patients during dose stabilization, patients transitioning to new regimens (pump starts, new insulin formulations), or those experiencing significant life changes (new school, puberty, family disruption). Well-controlled patients on stable regimens likely don’t need weekly contact.
Structuring telehealth visits: Each visit should include specific CGM metric review (TIR, TAR, TBR, GMI, CV%), ambulatory glucose profile pattern recognition (fasting, post-meal, overnight), specific dose adjustment recommendations (written to patient/family), identification of behavioral factors (missed boluses, exercise patterns, school schedule issues), and clear goals for the coming week. Document consistently and track metrics over time.
Staffing considerations: The study used trained diabetes educators rather than physicians for weekly visits, which is likely essential for scalability. Physician involvement can be reserved for complex decisions or quarterly comprehensive visits. Consider whether your practice can train and support educators in this role, or whether partnership with a telehealth diabetes service might be needed.
Technology requirements: Patients need CGM with data sharing capability. Cloud-based CGM platforms (LibreView, Clarity, Carelink, t:connect, Glooko) allow remote data review before or during calls. Ensure families understand how to share data and that technical barriers are addressed early. Video capability is helpful but phone-only visits can work if CGM data is reviewed simultaneously via web portal.
How This Study Fits Into the Broader Evidence
This trial aligns with growing evidence supporting telemedicine in diabetes care. The landmark CONCEPTT trial in pregnancy and the DI:RECT study demonstrated that remote CGM data review improves outcomes. The COVID-19 pandemic produced numerous observational studies showing that telehealth diabetes care was at least non-inferior to in-person care, and in some populations, superior due to reduced barriers to access.
The 2023 ISPAD guidelines now recommend remote monitoring and telehealth as adjuncts to in-person care, particularly for patients not meeting glycemic targets. The ADA Standards of Care similarly support telehealth integration. However, reimbursement models, technology access, and staffing remain barriers to widespread implementation.
Automated insulin delivery (AID) systems represent a parallel approach to improving outcomes through more frequent dosing adjustments—but they make adjustments every 5 minutes, not weekly. For patients on MDI who cannot or choose not to use AID systems, intensive telehealth support may provide the next-best option for improved outcomes.
Limitations to Consider
The crossover design, while statistically efficient, may introduce carryover effects if knowledge gained during the intervention period persists into the control period. The 12-week duration is relatively short; sustainability of effects with longer or less intensive follow-up is unknown. The study used educator-led telehealth—implementation may vary with different staffing models. All participants were already on CGM; benefits in SMBG-only populations are unclear.
Bottom Line
Weekly structured telehealth visits with CGM data review significantly improve glycemic control in children and adolescents with poorly controlled type 1 diabetes, reducing HbA1c by 0.29% without increasing hypoglycemia. This study supports intensive remote monitoring as a scalable intervention for high-risk pediatric diabetes patients. The key elements are frequency (weekly), structure (protocol-driven CGM review), and actionable feedback (specific dose adjustments). Consider implementing intensive telehealth programs for patients above HbA1c target who could benefit from more frequent touchpoints than quarterly clinic visits allow.
Source: Asma Deeb, et al. “Effect of an Intensive, Integrated Telehealth Intervention on Glycemic Control in Children and Adolescents With Type 1 Diabetes Using Continuous Glucose Monitoring: A Randomized, Crossover Trial.” Read article here.
